Published in Clinical Oncology Week, November 21st, 2005
The phase II study will be conducted at multiple centers in North America and is expected to enroll up to 60 patients with secondary AML, patients with antecedent myelodysplastic syndrome or prior exposure to leukemogenic therapy. Patients will receive a daily dose of Xanafide for 5 days in combination with a standard dose of ara-C as a continuous infusion for 7 days. The primary endpoint of the study is the rate of complete remission, and secondary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.